Depression That Keeps Coming Back: Why Recurrent Depression in Brooklyn Deserves a Different Approach

There's a particular kind of exhaustion that comes not from a first episode of depression but from a third, or a fourth, or a fifth. Each time, you go through the process — the evaluation, the medication trial, the waiting, the partial improvement, the tapering off when things seem stable — and then, sometimes months later, sometimes years, it comes back. And each time it comes back, it carries with it a growing weight of demoralization about whether it's ever going to stop.

Recurrent depression is not the same clinical situation as a first episode of depression, and it doesn't always respond to the same approach. If you're in Brooklyn and you've been through this cycle more than once, understanding why recurrence happens and what it means for your treatment options is worth your time.

Why Depression Comes Back

Depression is not a condition that, once treated, leaves and stays gone for most people. Research suggests that roughly 50% of people who have a first depressive episode will have a second one. After a second episode, the likelihood of a third rises significantly. After three episodes, recurrence becomes more the expected pattern than the exception.

Several factors contribute to this:

Neurobiological sensitization. Each depressive episode appears to lower the threshold for the next one — a phenomenon called kindling. The brain becomes more sensitive to the triggers that initiate depression over time, meaning that episodes can occur with less identifiable precipitating stress.

Incomplete remission. Ending a depressive episode with residual symptoms — still not quite yourself, still some difficulty concentrating or sleeping, still a low-grade flatness — significantly increases relapse risk compared to achieving full remission. Partial treatment produces partial protection.

Undertreated biological vulnerability. Some people have a stronger underlying biological predisposition to depression that standard antidepressant courses don't fully address. Treating the episode without addressing the underlying vulnerability leaves the system exposed.

Inadequate maintenance treatment. Stopping medication too soon after remission is one of the most consistent predictors of relapse. Current evidence supports staying on antidepressants for at least 12 months after a first episode, and longer — often indefinitely — after multiple recurrences.

When the Standard Approach Isn't Holding

For some people with recurrent depression, the standard cycle of antidepressant trial, response, and maintenance eventually stops providing adequate coverage. Episodes become more frequent, the windows between them shorter, the response to restarting medication slower or less complete.

This is when the clinical picture warrants a different conversation — not just a new antidepressant, but a comprehensive reassessment of the full treatment approach.

Questions worth raising with a psychiatrist at this point:

• Has my maintenance duration been adequate after prior episodes?

• Is there a co-occurring condition — anxiety, ADHD, sleep disorder — that's been sustaining the vulnerability?

• Does my pattern of recurrence suggest a biological subtype that might respond better to a different pharmacological approach?

• Am I a candidate for advanced treatment options, including Spravato®?

Spravato® and Recurrent Depression

Spravato® (esketamine) is FDA-approved for treatment-resistant depression — but the clinical conversation around it increasingly includes patients with highly recurrent depression that, while technically responsive to antidepressants, keeps returning and becomes harder to treat each time.

The rationale is neurobiological. Esketamine works through the glutamate system, promoting synaptic plasticity and the rebuilding of neural connections that depression erodes. For patients whose depression keeps recurring — and whose neurobiological resilience to depressive episodes may be compromised — a treatment that works at the synaptic level represents a meaningfully different approach from one that simply modulates neurotransmitter availability.

Whether Spravato® is appropriate for recurrent depression that isn't technically treatment-resistant involves a clinical judgment that requires a thorough evaluation. It's a conversation worth having rather than a question with a predetermined answer.

Getting the Right Care in Brooklyn

Recurrent depression benefits from care that takes the longitudinal picture seriously — not just treating the current episode but understanding the pattern, addressing the full vulnerability, and building a maintenance strategy with enough depth to actually hold.

At Aurora Wellness, our Brooklyn team at 32 Court Street includes board-certified psychiatrists, PMHNPs, PA-Cs, and licensed therapists who work together within the same practice. For patients whose depression keeps returning despite standard treatment, we offer comprehensive reassessment, medication management, therapy, and Spravato® treatment for appropriate candidates. Telehealth psychiatric care and therapy are also available throughout New York State.

If your depression has come back more than once and the current approach isn't providing the stability you need, a fresh evaluation with a team that understands recurrent depression is worth pursuing.